 During Phase ll, depending on cancer type, groups of patients will be enrolled and receive varlilumab at a dose of either 3 mgkg every 2 weeks, 3 mgkg every 12 weeks, or 0.3 mgkg every 4 weeks in combination with nivolumab at 240 mg. 